HAGENS-BERMAN-securities-press-release.jpg
BGNE INVESTOR REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud
07 oct. 2019 20h05 HE | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Hagens Berman reminds BGNE investors that it has launched an investigation into BeiGene, Ltd. (NASDAQ: BGNE) regarding possible violations of Federal...
HAGENS-BERMAN-securities-press-release.jpg
BGNE INVESTOR REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud
30 sept. 2019 20h04 HE | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Hagens Berman reminds BGNE investors that it has launched an investigation into BeiGene, Ltd. (NASDAQ: BGNE) regarding possible violations of...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019
30 sept. 2019 06h00 HE | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019
26 sept. 2019 18h05 HE | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 26, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
Schall Firm Logo 2.jpg
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against BeiGene, Ltd. and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm
25 sept. 2019 09h55 HE | Schall Law
LOS ANGELES, Sept. 25, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd....
HAGENS-BERMAN-securities-press-release.jpg
BGNE INVESTIGATION REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud
23 sept. 2019 20h06 HE | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Hagens Berman reminds BGNE investors that it has launched an investigation into BeiGene, Ltd. (NASDAQ: BGNE) regarding possible violations of...
Schall Firm Logo 2.jpg
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
18 sept. 2019 10h50 HE | Schall Law
LOS ANGELES, Sept. 18, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd....
HAGENS-BERMAN-securities-press-release.jpg
BGNE SHAREHOLDER ALERT: Hagens Berman Reminds Investors in BeiGene, Ltd. (BGNE) of Ongoing Investigation of Possible Securities Fraud
17 sept. 2019 20h02 HE | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Hagens Berman reminds BGNE investors that it has launched an investigation into BeiGene, Ltd. (NASDAQ: BGNE) regarding possible violations of...
Schall Firm Logo 2.jpg
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
13 sept. 2019 17h06 HE | Schall Law
LOS ANGELES, Sept. 13, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd....
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)
11 sept. 2019 16h30 HE | BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...